Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy
- 1 June 2004
- journal article
- research article
- Published by Elsevier BV in Lung Cancer
- Vol. 44 (3), 311-316
- https://doi.org/10.1016/j.lungcan.2003.11.019
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- β-Tubulin mutational analysis: tantalizing findingsLung Cancer, 2002
- Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemiaThe Lancet, 2002
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trialThe Lancet, 2001
- Predictive molecular markers in non–small cell lung cancerCurrent Opinion in Oncology, 2001
- DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytesMutation Research/DNA Repair, 2000
- Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control studyBlood, 2000
- DNA excision repair pathwaysCurrent Opinion in Genetics & Development, 1997
- New Chemotherapeutic Agents for Non-small Cell Lung CancerChest, 1995
- Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.JCI Insight, 1994